Cargando…

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers

BACKGROUND: Five to 25% of patients with PD carry glucocerebrosidase gene mutations, and 10% to 30% of glucocerebrosidase carriers will develop PD by age 80. Stratification of PD risk in glucocerebrosidase carriers provides an opportunity to target disease‐modifying therapies. OBJECTIVE: Cross‐secti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullin, Stephen, Beavan, Michelle, Bestwick, Jonathan, McNeill, Alisdair, Proukakis, Christos, Cox, Timothy, Hughes, Derralynn, Mehta, Atul, Zetterberg, Henrik, Schapira, Anthony H.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790937/
https://www.ncbi.nlm.nih.gov/pubmed/31251436
http://dx.doi.org/10.1002/mds.27775
_version_ 1783458878010163200
author Mullin, Stephen
Beavan, Michelle
Bestwick, Jonathan
McNeill, Alisdair
Proukakis, Christos
Cox, Timothy
Hughes, Derralynn
Mehta, Atul
Zetterberg, Henrik
Schapira, Anthony H.V.
author_facet Mullin, Stephen
Beavan, Michelle
Bestwick, Jonathan
McNeill, Alisdair
Proukakis, Christos
Cox, Timothy
Hughes, Derralynn
Mehta, Atul
Zetterberg, Henrik
Schapira, Anthony H.V.
author_sort Mullin, Stephen
collection PubMed
description BACKGROUND: Five to 25% of patients with PD carry glucocerebrosidase gene mutations, and 10% to 30% of glucocerebrosidase carriers will develop PD by age 80. Stratification of PD risk in glucocerebrosidase carriers provides an opportunity to target disease‐modifying therapies. OBJECTIVE: Cross‐sectional and longitudinal survey of prodromal PD signs among glucocerebrosidase carriers. DESIGN: Prospective assessment of 82 glucocerebrosidase mutation carriers and 35 controls over 4 to 5 years for prodromal clinical PD features. RESULTS: At all time points, olfactory (measured using University of Pennsylvania Smell Identification Test) and cognitive (Montreal Cognitive Assessment) function and the International Parkinson and Movement Disorder Society UPDRS parts II and III scores were significantly worse amongst glucocerebrosidase mutation carriers. Progression to microsmia (odds ratio: 8.5; 95% confidence interval: 2.6–28.2; P < 0.05) and mild cognitive impairment (odds ratio: 4.2; 95% confidence interval: 1.1–16.6; P < 0.05) were more rapid compared to controls. Those with worse olfaction also had worse cognition (OR, 1.5; 95% CI: 0.0–2.8; P < 0.05) and depression (OR, 1.3; 95% CI: 0.6–2.8; P < 0.05). No participants reached the MDS prodromal PD diagnostic criteria before PD diagnosis. One participant developed PD. He did not fulfill the International Parkinson and Movement Disorder Society prodromal PD criteria before diagnosis. CONCLUSION: Assessment of individual and clustered PD prodromal features may serve as a useful tool to identify high‐risk subjects for conversion to PD. As a result of the low conversion rate in our glucocerebrosidase mutation carriers to date, prospective validation is needed in larger cohorts to establish the profile of these features in PD convertors. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
format Online
Article
Text
id pubmed-6790937
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-67909372019-10-21 Evolution and clustering of prodromal parkinsonian features in GBA1 carriers Mullin, Stephen Beavan, Michelle Bestwick, Jonathan McNeill, Alisdair Proukakis, Christos Cox, Timothy Hughes, Derralynn Mehta, Atul Zetterberg, Henrik Schapira, Anthony H.V. Mov Disord Research Articles BACKGROUND: Five to 25% of patients with PD carry glucocerebrosidase gene mutations, and 10% to 30% of glucocerebrosidase carriers will develop PD by age 80. Stratification of PD risk in glucocerebrosidase carriers provides an opportunity to target disease‐modifying therapies. OBJECTIVE: Cross‐sectional and longitudinal survey of prodromal PD signs among glucocerebrosidase carriers. DESIGN: Prospective assessment of 82 glucocerebrosidase mutation carriers and 35 controls over 4 to 5 years for prodromal clinical PD features. RESULTS: At all time points, olfactory (measured using University of Pennsylvania Smell Identification Test) and cognitive (Montreal Cognitive Assessment) function and the International Parkinson and Movement Disorder Society UPDRS parts II and III scores were significantly worse amongst glucocerebrosidase mutation carriers. Progression to microsmia (odds ratio: 8.5; 95% confidence interval: 2.6–28.2; P < 0.05) and mild cognitive impairment (odds ratio: 4.2; 95% confidence interval: 1.1–16.6; P < 0.05) were more rapid compared to controls. Those with worse olfaction also had worse cognition (OR, 1.5; 95% CI: 0.0–2.8; P < 0.05) and depression (OR, 1.3; 95% CI: 0.6–2.8; P < 0.05). No participants reached the MDS prodromal PD diagnostic criteria before PD diagnosis. One participant developed PD. He did not fulfill the International Parkinson and Movement Disorder Society prodromal PD criteria before diagnosis. CONCLUSION: Assessment of individual and clustered PD prodromal features may serve as a useful tool to identify high‐risk subjects for conversion to PD. As a result of the low conversion rate in our glucocerebrosidase mutation carriers to date, prospective validation is needed in larger cohorts to establish the profile of these features in PD convertors. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. John Wiley & Sons, Inc. 2019-06-28 2019-09 /pmc/articles/PMC6790937/ /pubmed/31251436 http://dx.doi.org/10.1002/mds.27775 Text en © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Mullin, Stephen
Beavan, Michelle
Bestwick, Jonathan
McNeill, Alisdair
Proukakis, Christos
Cox, Timothy
Hughes, Derralynn
Mehta, Atul
Zetterberg, Henrik
Schapira, Anthony H.V.
Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title_full Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title_fullStr Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title_full_unstemmed Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title_short Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
title_sort evolution and clustering of prodromal parkinsonian features in gba1 carriers
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790937/
https://www.ncbi.nlm.nih.gov/pubmed/31251436
http://dx.doi.org/10.1002/mds.27775
work_keys_str_mv AT mullinstephen evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT beavanmichelle evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT bestwickjonathan evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT mcneillalisdair evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT proukakischristos evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT coxtimothy evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT hughesderralynn evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT mehtaatul evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT zetterberghenrik evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers
AT schapiraanthonyhv evolutionandclusteringofprodromalparkinsonianfeaturesingba1carriers